ストックスクリーナーアプリを入手
3.70
0.54%
-0.02
アフターアワーズ：
3.63
-0.07
-1.89%
前日終値:
$3.72
開ける：
$3.75
24時間の取引高:
152.27K
Relative Volume:
0.62
時価総額：
$244.47M
収益：
$7.69M
当期純損益:
$-17.65M
株価収益率:
-9.8851
EPS:
-0.3743
ネットキャッシュフロー:
$-15.72M
1週間 パフォーマンス:
-9.98%
1か月 パフォーマンス:
+2.49%
6か月 パフォーマンス:
+13.85%
1年 パフォーマンス:
+84.08%
1日の値動き範囲:
$3.58
$3.825
1週間の範囲:
$3.58
$4.2392
52週間の値動き範囲:
$1.30
$4.85
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.70 | 247.77M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Guggenheim | Buy |
| 2025-08-06 | 開始されました | Leerink Partners | Outperform |
| 2025-01-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 開始されました | China Renaissance | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Adagene Inc Adr (ADAG) 最新ニュース
Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake - Stock Titan
Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results - Stock Titan
Adagene’s Cancer Trial Results Expected in 1H 2027 - Stock Titan
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026 - The Globe and Mail
Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K - Stock Titan
ADAG - Finviz
Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG) - TradingView
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineLate Stage Breakouts - dars.gov.et
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Presents Two Posters at AACR 2026 with New Data - GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
Analysts Offer Predictions for Adagene FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Inc Adr (ADAG) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):